Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer

  • Guan Yu Xiao
  • , Xiaochao Tan
  • , Bertha L. Rodriguez
  • , Don L. Gibbons
  • , Shike Wang
  • , Chao Wu
  • , Xin Liu
  • , Jiang Yu
  • , Mayra E. Vasquez
  • , Hai T. Tran
  • , Jun Xu
  • , William K. Russell
  • , Cara Haymaker
  • , Younghee Lee
  • , Jianjun Zhang
  • , Luisa Solis
  • , Ignacio I. Wistuba
  • , Jonathan M. Kurie

Producción científica: Articlerevisión exhaustiva

30 Citas (Scopus)

Resumen

Epithelial-to-mesenchymal transition (EMT) underlies immunosuppression, drug resistance, and metastasis in epithelial malignancies. However, the way in which EMT orchestrates disparate biological processes remains unclear. Here, we identify an EMT-activated vesicular trafficking network that coordinates promigratory focal adhesion dynamics with an immunosuppressive secretory program in lung adenocarcinoma (LUAD). The EMT-activating transcription factor ZEB1 drives exocytotic vesicular trafficking by relieving Rab6A, Rab8A, and guanine nucleotide exchange factors from miR-148a-dependent silencing, thereby facilitating MMP14-dependent focal adhesion turnover in LUAD cells and autotaxin-mediated CD8+ T cell exhaustion, indicating that cell-intrinsic and extrinsic processes are linked through a microRNA that coordinates vesicular trafficking networks. Blockade of ZEB1-dependent secretion reactivates antitumor immunity and negates resistance to PD-L1 immune checkpoint blockade, an important clinical problem in LUAD. Thus, EMT activates exocytotic Rabs to drive a secretory program that promotes invasion and immunosuppression in LUAD.

Idioma originalEnglish
Número de artículoe2220276120
PublicaciónProceedings of the National Academy of Sciences of the United States of America
Volumen120
N.º28
DOI
EstadoPublished - jul 11 2023

Nota bibliográfica

Publisher Copyright:
Copyright © 2023 the Author(s).

Financiación

ACKNOWLEDGMENTS. This work was supported by the (NIH) through R01 CA181184 (to J.M.K.), R01 CA2111125 (to J.M.K.), K99 CA249048 (to G.-Y.X), NIH Lung Cancer SPORE grant P50 CA70907 (to J.M.K.) and by CPRIT-MIRA RP160652. J.M.K. holds the Gloria Lupton Tennison Distinguished Professorship in Lung Cancer.The work was also supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program, the Gil and Dody Weaver Foundation and Bill and Katie Weaver Charitable Trust, and the MD Anderson Cancer Center Support Grant P30 CA016672. This study was supported by the Translational Molecular Pathology-Immunoprofiling Moonshots Platform (TMP-IL) at the Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center.

FinanciadoresNúmero del financiador
CPRIT-MIRARP160652
Gil and Dody Weaver Foundation
National Institutes of Health (NIH)P50 CA70907, R01 CA2111125, K99 CA249048, R01 CA181184
University of Texas Anderson Cancer CenterP30 CA016672
Bill and Katie Weaver Charitable Trust

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • General

    Huella

    Profundice en los temas de investigación de 'EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer'. En conjunto forman una huella única.

    Citar esto